The global Oral Mucositis Market size is predicted to register 8.1% CAGR during the forecast period of 2019 to 2028, with a market price of USD 2,247 million in 2018. Oral mucositis is an acute inflammation or ulceration of the oral or oropharyngeal mucosal membranes. It can cause pain/discomfort, interfere with swallowing, eating, and speech, and may lead to infection. The global oral mucositis market is driven by factors like rising incidences of cancer globally and increasing oral mucositis drug development, according to the National Center for Biotechnology Information, oral mucositis occurs in up to 40% of cancer patients that receive chemotherapy and approaches 100% in the treatment of head and neck cancers. Additionally, according to National Cancer Institute, an estimated 1,735,350 new cases of cancer were diagnosed in the US in 2019.

Top Driver: Increase in the number of patients with head and neck cancers will drive the market growth

Rise in the number of patients with head and neck cancers globally is a prominent factor driving the growth of the oral mucositis market. According to the World Health Organization (WHO), globally around 400,000 cases of head cancer and 600,000 cases of neck cancer are reported every year, with an estimated 223,000 and 300,000 deaths, respectively, per year. Oral cancer accounts for 85% of the head and neck cancers. The American Cancer Society has estimated a total of 51,540 new cases of oral cavity and oropharyngeal cancer in the U.S in 2019. Rise in the number of patients with oral cancer is expected to drive the patient base of oral mucositis, as 40% of the patients undergoing cancer chemotherapy suffers from a certain degree of oral mucositis.

Chemotherapy to Make Crucial Contribution for Growth of Global Oral Mucositis Market

The market, supported cause, has been bifurcated into oral mucositis caused by chemotherapy, oral mucositis caused by radiotherapy, and oral mucositis caused by hematopoietic somatic cell transplantation

The global market, based on end user, has been segmented into hospitals, dental clinics, oncology hospitals, and research institutes. Based on cause, the oral mucositis caused by chemotherapy segment is expected to hold a major share in the market as chemotherapy is widely used as a treatment method for cancer. For example, according to the US Department of Health & Human Services, every year, about 650,000 cancer patients receive chemotherapy in an outpatient oncology clinic in the US. Based on user , the hospitals segment is predicted to carry a serious share within the market thanks to its close association with cancer availability of all possible treatment options.

 North America dominated to witness fastest growth in Global Oral Mucositis Market

The market within the Americas is predicted to dominate the oral mucositis market thanks to the increasing incidences of head and neck cancers. for instance , consistent with the American Society of Clinical Oncology (ASCO), head and neck cancer account for about 4% of all cancers within the US. In 2019, an estimated 65,410 people will develop head and neck cancer. High cases of cancer within the US and Canada is predicted to drive the market growth. Furthermore, increasing expenses in research by healthcare bodies engaged in improving oral mucositis treatment are the factors contributing to its largest share is predicted to fuel the expansion of the market during this region. The market in Europe showed a substantial amount of growth. this will be attributed to the presence of a well-established healthcare system, a rise in cancer diseases.

The market in Asia-Pacific is projected to possess a gentle rate of growth during the forecast period due to the increasing prevalence of cancer and increasing government initiatives for healthcare reforms. The market within the Middle East & Africa is projected to account for the smallest amount share of the worldwide market thanks to low per capita income within the region.

Players to Focus on Oral Mucositis Market

Strategies are proving essential in taking the oral mucositis market forward. Influential companies are getting involved in a merger, acquisition, new product launch, collaborations, and other tactics to stay abreast in this market.

Catalent acquired Juniper Pharmaceuticals : For instance, Catalent acquired Juniper Pharmaceuticals to expand its market hold and cement its foothold in Europe. AMAG Pharmaceuticals is planning on diversification by completing divestiture in cord blood registry.

Some of the players operating for the oral mucositis are

• Izun Pharmaceutical Ltd
• Shoreline Pharmaceuticals Inc.
• Himalaya (India)
• AMAG Pharmaceuticals Inc.
• Kinnear Pharmaceuticals
• Celleutix Corporation
• Soligenix Inc.
• Oragenics
• Soligenix, Inc

Scope of the Report

By Cause

• Oral Mucositis Caused by Chemotherapy
• Oral Mucositis Caused by Radiotherapy
• Oral Mucositis Caused by Hematopoietic Stem Cell Transplantation

By End user

• Hospitals
• dental clinics
• oncology hospitals

By Region

• North America
• Europe
• Asia Pacific
• SAMEA

Key Reasons to Purchase this Report 

1. It provides a technological development map over time to understand the growth rate of the industry.

2. The report offers a dynamic method to various factors that drive or restrain the growth of the market.

3. It renders definite analysis for changing competitive dynamics.

4. It builds a seven-year estimate based on how the market is predicted to grow.